These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 17088091

  • 1. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.
    Beier J, Chanez P, Martinot JB, Schreurs AJ, Tkácová R, Bao W, Jack D, Higgins M.
    Pulm Pharmacol Ther; 2007; 20(6):740-9. PubMed ID: 17088091
    [Abstract] [Full Text] [Related]

  • 2. Tolerability of indacaterol, a novel once-daily beta2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study.
    Yang WH, Martinot JB, Pohunek P, Beier J, Magula D, Cameron R, Owen R, Higgins M.
    Ann Allergy Asthma Immunol; 2007 Dec; 99(6):555-61. PubMed ID: 18219838
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B.
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [Abstract] [Full Text] [Related]

  • 4. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
    Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B, INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators.
    Thorax; 2010 Jun; 65(6):473-9. PubMed ID: 20522841
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study.
    Kinoshita M, Lee SH, Hang LW, Ichinose M, Hosoe M, Okino N, Prasad N, Kramer B, Fukuchi Y, Indacaterol Asian COPD Study Investigators.
    Respirology; 2012 Feb; 17(2):379-89. PubMed ID: 22122202
    [Abstract] [Full Text] [Related]

  • 7. Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study.
    Laforce C, Aumann J, de Teresa Parreño L, Iqbal A, Young D, Owen R, Higgins M, Kramer B, INTEGRAL Study Investigators.
    Pulm Pharmacol Ther; 2011 Feb; 24(1):162-8. PubMed ID: 20619353
    [Abstract] [Full Text] [Related]

  • 8. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.
    Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, Kramer B, INHANCE Study Investigators.
    Am J Respir Crit Care Med; 2010 Jul 15; 182(2):155-62. PubMed ID: 20463178
    [Abstract] [Full Text] [Related]

  • 9. Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients.
    Van de Maele B, Fabbri LM, Martin C, Horton R, Dolker M, Overend T.
    COPD; 2010 Dec 15; 7(6):418-27. PubMed ID: 21166630
    [Abstract] [Full Text] [Related]

  • 10. Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma.
    Beeh KM, Derom E, Kanniess F, Cameron R, Higgins M, van As A.
    Eur Respir J; 2007 May 15; 29(5):871-8. PubMed ID: 17251236
    [Abstract] [Full Text] [Related]

  • 11. Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study.
    LaForce C, Alexander M, Deckelmann R, Fabbri LM, Aisanov Z, Cameron R, Owen R, Higgins M.
    Allergy; 2008 Jan 15; 63(1):103-11. PubMed ID: 18053019
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
    Dahl R, Chapman KR, Rudolf M, Mehta R, Kho P, Alagappan VK, Chen H, Banerji D.
    Respir Med; 2013 Oct 15; 107(10):1558-67. PubMed ID: 23867808
    [Abstract] [Full Text] [Related]

  • 13. Bronchodilator effects of indacaterol and formoterol in patients with COPD.
    Beier J, Beeh KM, Brookman L, Peachey G, Hmissi A, Pascoe S.
    Pulm Pharmacol Ther; 2009 Dec 15; 22(6):492-6. PubMed ID: 19465142
    [Abstract] [Full Text] [Related]

  • 14. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Hanrahan JP.
    Clin Ther; 2007 Feb 15; 29(2):261-78. PubMed ID: 17472819
    [Abstract] [Full Text] [Related]

  • 15. Bronchodilator efficacy of single doses of indacaterol in Japanese patients with COPD: A randomised, double-blind, placebo-controlled trial.
    Kato M, Makita H, Uemura K, Fukuchi Y, Hosoe M, Emery C, Higgins M, Kramer B.
    Allergol Int; 2010 Sep 15; 59(3):285-293. PubMed ID: 20567133
    [Abstract] [Full Text] [Related]

  • 16. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design.
    Barnes PJ, Pocock SJ, Magnussen H, Iqbal A, Kramer B, Higgins M, Lawrence D.
    Pulm Pharmacol Ther; 2010 Jun 15; 23(3):165-71. PubMed ID: 20080201
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study.
    Feldman G, Siler T, Prasad N, Jack D, Piggott S, Owen R, Higgins M, Kramer B, INLIGHT 1 study group.
    BMC Pulm Med; 2010 Mar 08; 10():11. PubMed ID: 20211002
    [Abstract] [Full Text] [Related]

  • 18. 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol.
    Bauwens O, Ninane V, Van de Maele B, Firth R, Dong F, Owen R, Higgins M.
    Curr Med Res Opin; 2009 Feb 08; 25(2):463-70. PubMed ID: 19192991
    [Abstract] [Full Text] [Related]

  • 19. Indacaterol once-daily is equally effective dosed in the evening or morning in COPD.
    Magnussen H, Verkindre C, Jack D, Jadayel D, Henley M, Woessner R, Higgins M, Kramer B, INPUT study investigators.
    Respir Med; 2010 Dec 08; 104(12):1869-76. PubMed ID: 20850959
    [Abstract] [Full Text] [Related]

  • 20. Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthma.
    Pearlman DS, Greos L, LaForce C, Orevillo CJ, Owen R, Higgins M.
    Ann Allergy Asthma Immunol; 2008 Jul 08; 101(1):90-5. PubMed ID: 18681090
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.